{"ok":true,"trend":{"id":279522,"platform":"news","region":"global","key":"anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma","title":"Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma","url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNeWt1RzRGOUlLNGo0eFdUckVKQTNYR1dHMWc1WFdHUExoSkFyVkhVdXQ4RGFxZm9DNmFFMDFYQ05JQlFHMDhGOGEyVHFJVUtLd3ZuY2hSOFhuaUFubE40bVVOVTZIWW5hOUF4TVdJTDRFa1k5QS1XWWNxNXZlTHhRbmxfOE5ZNGhQUHR6Q1FkSE52endxYjQtQ3VkY3VVQWVMU0NMa2ZRU19POHNqb21wZEQwR1hVNVh0VzZxdlNVTlZ3Qjd0Q2hLajRVWF8xNzFpTTFCeHRoWE16bXZkMTJFdlJmTExXWVAxZkE?oc=5","first_seen":"2026-09-28T21:32:53.398855Z","last_seen":"2026-09-29T00:16:52.645705Z","last_rank":36,"peak_rank":27,"last_volume":null,"peak_volume":0,"seen_count":3,"score":0.6609375,"category_hint":"medicine","section":"health","category":"medicine","summary":"Anitocabtagene autoleucel, a cell therapy, is associated with sustained clinical responses in patients with heavily pretreated multiple myeloma, according to a report in medical news. The finding is notable for a disease where patients who have exhausted standard lines of treatment typically face poor outcomes. Clinicians are watching whether such CAR-T approaches can extend durable remissions.","why":"New evidence on a cell therapy offering durable benefit to patients with limited treatment options is drawing medical attention.","tone":"positive","entities":["Anitocabtagene autoleucel","multiple myeloma"],"summarized_at":"2026-09-28T21:34:51.685696Z","meta":{"via":"scan","lang":"en","term":"medicine","source":"2minutemedicine.com","generic":0.04,"published":"Mon, 28 Sep 2026 19:43:28 GMT"},"nw":0.41,"promo":0.02,"kind":"news_event","importance":1.5,"hidden":false,"hide_reason":null,"judged_at":"2026-09-28T21:32:53.731700Z","title_en":"Anitocabtagene autoleucel shows sustained response in multiple myeloma","section_name":"Health","category_name":"Medicine","timeline":[{"captured_at":"2026-09-28T21:32:53.398855Z","rank":27,"volume":null},{"captured_at":"2026-09-28T22:54:52.994719Z","rank":32,"volume":null},{"captured_at":"2026-09-29T00:16:52.645705Z","rank":36,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNeWt1RzRGOUlLNGo0eFdUckVKQTNYR1dHMWc1WFdHUExoSkFyVkhVdXQ4RGFxZm9DNmFFMDFYQ05JQlFHMDhGOGEyVHFJVUtLd3ZuY2hSOFhuaUFubE40bVVOVTZIWW5hOUF4TVdJTDRFa1k5QS1XWWNxNXZlTHhRbmxfOE5ZNGhQUHR6Q1FkSE52endxYjQtQ3VkY3VVQWVMU0NMa2ZRU19POHNqb21wZEQwR1hVNVh0VzZxdlNVTlZ3Qjd0Q2hLajRVWF8xNzFpTTFCeHRoWE16bXZkMTJFdlJmTExXWVAxZkE?oc=5","author":"2 Minute Medicine","title":"Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma","snippet":null,"posted_at":"2026-09-28T19:43:28Z","likes":null},{"platform":"news","url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNZVVxNjVORUN1VVJDY2tNSzJSMU9ZTU1GVTRDbW05Yk9icy0tN1RaYXdoak5CZkRGZ29WSWtmVmV6WnZNSk1vQjE4Ym8wbXBjdUN3UTJ3VE8tQ0JDdnJwTFVFRExRZlBIOXVJM1Y5Q01JZUhvWGE1bEIwU3c4R1VPRjYxSkxESVRWOUlOaHlnWk5QQl9pRGZPOHVNcVlnLVljenRBeUMwMjhrcjA2NFpINWtfcDE1T3RRWlRqc0VpS1kxbWdDOWpEVDQ5RjFkNmhPN2dReGpJb2o?oc=5","author":"2 Minute Medicine","title":"Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma","snippet":null,"posted_at":"2026-09-28T19:43:27Z","likes":null}],"elsewhere":[],"window":"7d"}}